ADC Therapeutics shareholders approve all 12 proposals at 2024 AGM, including director re-elections and compensation

ADC Therapeutics SA

Shareholders approved management report, annual financial statements, and discharge of directors/executive committee for FY2023.
All nine directors reelected; compensation committee members, independent proxy, and PwC auditors also reelected.
Binding approval: board comp cap $2M; fixed exec comp cap $3M (FY2025); variable exec comp cap $10M (FY2024).
Advisory votes: compensation report and say-on-pay passed; shareholders recommended annual frequency, adopted by company.
Articles of association amended in six areas including shareholder rights, meetings, and conditional share capital flexibility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.